title: [Interest of a sterilised anti-burning gel in radiation dermatitis: results of a comparative study].
abstract: Trial objectives were to assess effectiveness and tolerance of sterilized Avène thermal spring water anti burning gel (ATSW gel) in prevention of radiation dermatitis in adults irradiated (6 weeks) for breast (n=61) or head and neck (n=8) cancer. Patients included in this open labelled, 2 parallel groups, multicentric study, were randomly assigned to apply five times daily for ten weeks either the Avène spring water gel (n=35) or trolamine cream (n=34). The median of emergence of the first objective radiation dermatitis signs was 31 days in the ATSW gel group and 29 days in the control group (p=0,924). The median incidence for pruritus in patients of the ETA gel group was 46 days versus 27 days (p=0,028) and 44 days versus 24 days for pain (p=0,426). Global efficacy was <<very good>> in 46,7 % of patients of the ETA gel group versus 17,2 % (p=0,029) and tolerance was <<very good>> in 65,5 % of the ETA gel group versus 40,7 % (p=0,107). No radionecrosis was observed. In conclusion, the efficacy of the Avène spring water gel was similar to the control product in prophylaxis of radiation dermatitis. Tolerance was better and the pruritus was significantly more delayed in patients who applied the Avène spring water gel than in controls.
authors.affiliation: Institut de Recherche Pierre Fabre, Parc technologique du canal, 4 rue Marie Curie, BP 22132, 31521 Ramonville cedex, France. virginie.ribet@pierre-fabre.com
authors.forename: V
authors.initials: V
authors.lastname: Ribet
authors.forename: S
authors.initials: S
authors.lastname: Salas
authors.forename: J M
authors.initials: JM
authors.lastname: Levecq
authors.forename: L
authors.initials: L
authors.lastname: Bastit
authors.forename: M
authors.initials: M
authors.lastname: Alfonsi
authors.forename: G
authors.initials: G
authors.lastname: De Rauglaudre
authors.forename: B
authors.initials: B
authors.lastname: Talon
authors.forename: C
authors.initials: C
authors.lastname: Allavena
authors.forename: C
authors.initials: C
authors.lastname: Miot
authors.forename: J M
authors.initials: JM
authors.lastname: Boisseau
authors.forename: P
authors.initials: P
authors.lastname: Faure
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000532:radiotherapy; D003627:Data Interpretation, Statistical; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004890:Erythema / Q000517:prevention & control; D004983:Ethanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D008875:Middle Aged; D008900:Mineral Waters / Q000008:administration & dosage* / Q000627:therapeutic use; D009824:Ointments; D010039:Otorhinolaryngologic Neoplasms / Q000532:radiotherapy; D011537:Pruritus / Q000517:prevention & control; D011855:Radiodermatitis / Q000188:drug therapy / Q000517:prevention & control*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D004983:Ethanolamines; D005782:Gels; D008900:Mineral Waters; D009824:Ointments; C009546:triethanolamine